ABSTRACT
Objective To compare the effects of upstream versus downstream tirofiban on tissure level perfu-sion and troponin Ⅰ release in high-risk non-ST-segment elevation acute coronary patients treated with percutaneous coronary intervention. Methods We randomized 138 non-ST-segment elevation acute coronary syndrome patients un-dergoing PCI to receive upstream(in the coronary care unit) and downstream(just prior to PCI) tirofiban. We com-pared the effects between the two drug regimens on tissue-level peffusion using Thrombolysis In Mycardial Infarction (TIMI) fram count,the TIMI myocardial perfusion grade(TMPG) and cardiac tropinin Ⅰ (cTn Ⅰ) release before and after PCI. Results There was no significant difference between two groups in TIMI 3 flow(P>0.05). High percent-age of TMPG 3 perfusion were observed in upstream tirofiban group than in downstream tirofiban group (P < 0.05). Post-procedual cTnI elevation was significantly less frequent among patients in the upstream group (P < 0.05). The cTnI level after PCI was significantly lower with upstream tirofiban compared with downstream tirofiban group (P<0.05). Conclusion Among high-risk non-ST-segment elevation ACS patients treated with an early invasive strategy, upstream tirofiban is associated with improved tissue-level perfusion and attenuated myocardial damage.
ABSTRACT
Objective To investigate the relationship between blood glucose levels and severity of coronary stenosis in hypertensive patients. Methods Blood pressure, fasting plasma glucose, 2 h plasma glucose, clinical features and coronary angiographic findings were analyzed retrospectively in 540 patients with essential hypertension. Acoording 2 h plasma glucose, patients were stratified into three group: group 1: 2h plasma glucose
ABSTRACT
Objective To explore the therapeutic effect of irbesartan treatment on left ventricular remodeing after acute myocardial infarction by 2D Doppler technique.Methods 85 patients with AMI were selected into the study.42 patients were randomized to conventional treatment group,43 patients to irbesartan treatment group.At first week and 26 week after AMI,the left ventricular myocardium weight(LVMW) and diastolic volume(LVDV) were measured by echocardiogram,and the parameters of left ventricular systolic and diastolic function were measured by echocardiogram.Results (1)At 26 week,LVDV and LVMW in irbesartan treatment groups were significantly decreased as compared with conventional treatment group,left ventricular eiection fraction(LVEF) in irbesartan group was increased.(2)PE(peak E-wave velocity) and PFR(peak filling rate) in irbesartan group were increased as compared with conventional group.Conclusion Irbesaratan might significantly reduce myocardial dilatation of left ventricle,decrease LVMW after AMI and improve left ventricle function.
ABSTRACT
@#ObjectiveTo investigate the correlation of lipids and lipoproteins with cardiac function in patients with coronary heart disease (CHD).MethodsParameters of blood pressure, serum lipids and lipoproteins, clinical features, radionuclide ventriculographic and coronary angiographic findings were analyzed retrospectively in 584 CHD patients treated with standard treatment.ResultsThe left cardiac dysfunction of CHD patients was correlative positively with age, systolic blood pressure (SBP), diastolic blood pressure (DBP), blood glucose, body mass index (BMI), smoking, total cholesterol(TC) and low density lipoprotein cholesterol(LDL-ch) significantly(P<0.001), not correlative with high density lipoprotein-cholesterol (HDL-ch). The left ventricular ejection fraction (LVEF) and left ventricular peak filling rate (LVPFR) were decreased along with the levels of TC and LDL-ch increased (P<0.05～0.01).ConclusionTC and LDL-ch are positively correlative with left cardiac dysfunction in CHD patients. In order to reduce cardiac damage of CHD associated with hyperlipoidemia, more attention should be paid to the amelioration of coronary arteriosclerosis and the reduction of serum lipids and lipoproteins.
ABSTRACT
Objective To evalute the feasibility and safety of sirolimus (rapamycin)-eluting stent for the treatment of in-stent restenosis (ISR). Methods Eleven patients with ISR were treated with one or more Cypher~ TM sirolimus-eluting stents. All these patients received angiographic follow-up at 6 months. Results The success rate of the procedure was 100%. All patients were free of angina after 6 months. There were no repeat revascularizations, stent thrombosis or major adverse clinical events during the follow up period. No ISR was noted in the follow-up coronary angiography. Conclusion This study demonstrates the safety and potential of sirolimus-eluting stents for the treatment of ISR.